Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Lilly, Foghorn part ways; Wave’s FDA-approved plans

The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

Cheap, Common Drug Linked To Far Lower Dementia Risk—But Only For Some

Low-dose aspirin was associated with a 70 percent lower risk of dementia among those with a specific platelet count.

  • Low-dose aspirin may reduce dementia risk for certain individuals with specific genetics.
  • Aspirin increases serious bleeding risk by 104% compared to placebo.
  • Researchers urge personalized approach to dementia prevention based on findings.

More from Thursday 1 October →